What Will Retatrutide Cost When Lilly Launches?
No brand name. No approved Australian product. No pharmacy price. Anyone giving a precise launch price today is guessing.
Direct answer
Lilly hasn't launched an Australian retatrutide brand or official pharmacy price as of 23 May 2026.
Reviewed for
No brand-name claim
No official Australian price claim
Medicine versus vial-price distinction
Published 23 May 2026. Medical reviewer pending. No clinician credential is claimed.
No brand name yet
Direct answer
Retatrutide is the compound name, not an Australian commercial brand name.
Retatrutide is the international non-proprietary name. It's the compound name, not the commercial brand name.
Lilly hasn't launched an Australian retatrutide brand as of 23 May 2026.
No pharmacy price yet
Direct answer
There's no official Australian pharmacy price without TGA approval and launch.
Without TGA approval and launch, there's no official private Australian pharmacy price and no PBS price.
Any number you see today is either a forecast based on other GLP-1 medicines or a vial price from a research peptide seller.
Two prices, two markets
Direct answer
Don't compare future medicine pricing with current peptide-market pricing as if they're the same market.
The future medicine price belongs to Lilly, pharmacies, insurers, and PBS decisions. The current vial price belongs to peptide sellers and the records they show before payment.
Don't mix the two. A cheap vial with no COA isn't a bargain. It's an unknown.
Research peptides are not approved by the TGA for human use. Supplier links are for seller checks and buyer-protection review, not medical advice.
How we reviewed this article
This article was checked against primary source material, regulator pages, and the supplier-proof boundary used across this site. The goal is to keep what will retatrutide cost when lilly launches? useful without turning it into medical advice or a fake clinical recommendation.
Checked points
No brand-name claim
No official Australian price claim
Medicine versus vial-price distinction